Non-steroid receptor-mediated antiproliferative activity of styrylpyrone derivative in human breast cancer cell lines.
The antiproliferative activity of a styrylpyrone derivative (SPD) plant extract, was studied in three different human breast cancer cell lines in culture, and was compared with tamoxifen. The number of living cells was evaluated by Methylene Blue staining technique. SPD showed strong antiproliferative activity in estrogen receptor (ER) and progestin receptor (PgR) positive MCF-7 cells (EC50 = 6.30 x 10(-7) M) and receptor-negative MDA-MB-231 (EC50 = 5.62 x 10(-7) M), but it partially inhibited the high progestin receptor positive T47D cells (EC50 = 1.58 x 10(-6) M). Whereas tamoxifen, a nonsteroidal antiestrogen exhibited strong inhibition on MCF-7 cells (EC50 = 1.41 x 10(-6) M) and partial inhibition on T47D cells (EC50 = 2.5 x 10(-6) M), but did not affect the MDA-MB-231 cells in the concentration range 0.1 nM-1 microM (EC50 = 5.01 microM). At the same concentration range SPD and tamoxifen did not inhibit the proliferation of normal human liver cell line CCL 13 and normal bovine kidney MDBK; whereas adriamycin, a common chemotherapy drug for the treatment of advance cancer, caused 95% inhibition at 10(-6) M. Competitive binding studies showed SPD had no ability to inhibit the binding of [3H]estradiol and [3H]progesterone to ER and PgR, respectively but, tamoxifen exhibited affinity for ER. Therefore, it can be concluded that the antiproliferative activity of SPD was selective towards breast cancer cell lines and not mediated by ER or PgR.
Pihie
A H
AH
Department of Biochemistry, Faculty of Life Sciences, Universiti Kebangsaan Malaysia, Bangi, Selangor Darul Ehsan, Malaysia.
Stanslas
J
J
Din
L B
LB
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D001667:Binding, Competitive; D001943:Breast Neoplasms; D002417:Cattle; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000633:toxicity; D004958:Estradiol / Q000378:metabolism; D005260:Female; D006801:Humans; D007668:Kidney; D008099:Liver / Q000166:cytology / Q000187:drug effects; D011374:Progesterone / Q000378:metabolism; D011753:Pyrones / Q000633:toxicity*; D011960:Receptors, Estrogen / Q000187:drug effects / Q000378:metabolism; D011980:Receptors, Progesterone / Q000187:drug effects / Q000378:metabolism; D013629:Tamoxifen / Q000633:toxicity; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D011753:Pyrones; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; C103280:goniothalamin; D011374:Progesterone; D004958:Estradiol; D004317:Doxorubicin